BPC-157 and TB-500 are sold together as a healing “stack,” sometimes premixed in a single vial. The pitch is that two peptides with different mechanisms should repair tendons and joints faster than either alone. That is a reasonable-sounding hypothesis, and it has been tested exactly once, in rats. This page covers what that test found, and what is known about each half. It sits under the recovery goal.
The one controlled study of the pair
A 2026 study cut and surgically repaired the Achilles tendon in 32 male rats, then split them into four groups of eight [1]. One group got nothing extra, one BPC-157 at 10 µg/kg a day, one TB-500 at 60 µg/kg a day, and one both. The peptides were injected into the abdominal cavity daily for four weeks.
TB-500 alone gave the only significant biomechanical gain, a higher load before the tendon failed (p < 0.05). Tissue scores improved significantly with TB-500 alone (p = 0.016) and with the combination (p = 0.040), while BPC-157 alone improved them numerically but not significantly [1].
The authors’ own conclusion is the key line: combining the two did not add benefit over either agent alone. They suggest the two may act on shared downstream pathways, and flag that idea as needing its own test. This was an exploratory study, in rats, at four weeks, with one dose of each.
What each half brings: BPC-157
BPC-157 is a 15-amino-acid peptide that its developers call a stable gastric pentadecapeptide. In a 2003 study, rats with a cut Achilles tendon given BPC-157 into the abdominal cavity had better strength, function and tissue scores over 14 days than controls given saline [2].
In people, the evidence is far thinner, and it is laid out in what the human evidence on BPC-157 shows.
What each half brings: TB-500
TB-500 is usually described as a synthetic thymosin beta-4. The FDA disagrees: its July 2026 briefing states that thymosin beta-4 and TB-500 are not the same substance, and that it found no case reports of TB-500 use in people in the published literature [6]. The FDA lists TB-500 as a seven-amino-acid fragment of thymosin beta-4 [7], which is a 43-amino-acid protein [3].
The full protein does have a human trial, and it is often borrowed to support TB-500. A phase 2 trial in 73 people with venous leg ulcers applied thymosin beta-4 as a topical gel [3]. Safety was comparable to placebo, and the authors suggest a 0.03% dose may speed healing. That was a skin gel of a different molecule, not an injected fragment. More on this is in what the evidence on TB-500 shows.
What has been reported in people
A retrospective chart review from one clinic surveyed 16 patients by phone after knee injections of BPC-157, alone or with thymosin beta-4. Four had received both, and three of those four reported significant relief. [4]
That review had no control group, no standard outcome measure and follow-up by phone months later. It cannot separate the peptides from the injection itself, from time, or from expectation.
The FDA’s July 2026 briefing on BPC-157 records one adverse-event report for the pair [5]. A 40-year-old woman injected a product containing BPC-157 and TB-500, labeled “for research purposes only,” twice daily for joint and wound healing. She developed diffuse darkening of the skin and gums within a week, and the same reaction returned when she restarted. It stopped when she quit.
The FDA judged the reaction likely due to the product, but because it held two peptides, could not tell which one was responsible [5]. The wider BPC-157 safety record is in BPC-157 side effects, and what each study administered is in BPC-157 dosage.
What this means for you
The case for the stack rests on the idea that two mechanisms beat one. The only experiment to test that found they did not, in rats. No human dose of either peptide, alone or together, has been established, and nobody has run a clinical trial of the pair. The legal side of research-only peptides is in are peptides legal, and the human record for joints, compound by compound, is in peptides for joint pain.